The Christ Hospital | Lindner Research Newsroom

Dr. Dean Kereiakes provides commentary to Cardiology Today on the Champion Phoenix trial announcement at the American College of Cardiology Conference

2013-04-15T15:49:00.000-04:00

Click Here to View Video.

Video courtesy of Healio.com/Cardiology

Coronoary Arteries Healed with Dissolvable Stents - Radio Interview

2013-02-13T10:17:00.000-05:00

The 4 billion dollar coronary stent market is about to get bigger. Bioresorbable stents are performing well, giving patients and doctors more options. Cincinnati's Christ Hospital is the lead hospital in a national study. Ann Thompson reports how Absorb™ works and what it could mean for the market.

Click Here to Listen to the Interview with Dr. Dean Kereiakes

First Synergy stents implanted in EVOLVE II trial

2012-12-11T11:10:00.000-05:00

The first procedures to implant the novel Synergy bioabsorbable polymer drug-eluting stent as part of the EVOLVE II trial were recently performed at The Christ Hospital in Cincinnati. The procedures were performed by Thomas Broderick, MD, and Joseph Choo, MD, interventional cardiologists at the hospital.

Read The Full Article. (Click Here)

THE CHRIST HOSPITAL ON CUTTING EDGE OF NEW STENT TECHNOLOGY; IMPLANTS INVESTIGATIONAL NEW DEVICE

2012-12-03T11:49:00.001-05:00

CINCINNATI, Ohio – December 3, 2012 – Clinical scientists at The Christ Hospital’s Lindner Research Center are leading a worldwide study evaluating new breakthrough coronary stent technology that may make stenting easier and safer.

Read The Full Article. (Click Here)

Dr Sarembock on trans-catheter aortic valve replacement (TAVR)

2012-09-24T15:11:00.000-04:00

Nearly one in every eight Americans aged 75 and older will be diagnosed with valvular heart disease. Open-heart surgery has traditionally been the standard approach to treating this increasingly prevalent disease. But many elderly patients cannot undergo the rigors of conventional surgery, creating an urgent need for less invasive, non-surgical solutions for valve disease patients. On 10th September, Dr Sarembock gave our team some of his precious time in explaining the TAVR procedure.

Read The Full Article. (Click Here)

ACC: Novel therapy lowers LDL-C by 72%

2012-04-16T16:51:00.000-04:00

A novel monoclonal antibody lowered low density lipoprotein cholesterol (LDL-C) up to 72 percent in patients with primary hypercholesterolemia in a randomized, double-blind, placebo-controlled trial. The results were announced March 26 at the American College of Cardiology’s 61st scientific session and simultaneously published online in the Journal of the American College of Cardiology.

“This was a very sophisticated trial that gleaned a lot of information,” said co-author Dean J. Kereiakes, MD, medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, in an interview. The study was designed to test the safety and efficacy of the human monoclonal antibody SAR236553/REGN727.

Read the Full Article. (Click Here)

Watch the Video. (Click Here)

After an Unprecedented Request for a Retraction, A Close Look at the Data

2012-04-16T10:49:00.000-04:00

Guest Post from Edward J. Schloss, MD, the medical director of cardiac electrophysiology at Christ Hospital in Cincinnati, OH.

Last week, St. Jude Medical took the unusual step of requesting a retraction of an article accepted for publication in Heart Rhythm Journal. In this article Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads, Dr. Robert Hauser et al analyzed patient deaths in the FDA MAUDE database associated with St. Jude Medical and Medtronic ICD leads. This week, Dr. Douglas Zipes, Heart Rhythm editor, declined that request. (Please see my previous Cardiobrief coverage of Hauser’s article.)

Read the Full Article. (Click Here)

Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study

2012-04-13T13:56:00.001-04:00

Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc. /quotes/zigman/233680/quotes/nls/mdt MDT -1.16% announced today the start of the Medtronic IN.PACT SFA II study, the company’s first U.S. clinical trial for its line of IN.PACT drug-eluting balloons.

The first patients in this landmark study were treated this week by Dr. Ash Jain at Washington Hospital in Fremont, Calif., and Dr. Brian Bigelow at St. Vincent Hospital in Indianapolis; Dr. Monica Hunter at Christ Hospital in Cincinnati is planning to treat a patient in the study as early as next week. Drs. Jain, Bigelow and Hunter are the principal investigators at their respective trial site.

Read the Full Story. (PDF)

Researchers Explore Novel Technology Approach for Uncontrolled High Blood Pressure

2012-03-08T17:31:00.000-05:00

A radically different approach to treating high blood pressure – using a minimally invasive procedure– is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.

Read the full story. (PDF)

Report from the Riata ICD Lead Summit

2012-03-02T14:24:00.000-05:00

Edward J. Schloss, the medical director of cardiac electrophysiology at the Christ Hospital in Cincinnati, OH, attended the Riata ICD Lead Summit in January. Dr. Schloss has forwarded his summary of the meeting to CardioBrief.

Read the Full Summary.

New Stent Researched at Lindner Research Center Now Provides New Benefit to Coronary Artery Disease Patients

2012-02-24T16:50:00.000-05:00

The Christ Hospital is the first hospital in Greater Cincinnati to use the Resolute Integrity Drug-Eluting Stent (DES) from Medtronic for the treatment of coronary artery disease (CAD) in multiple patient types. The new device has been shown in a global series of clinical studies to yield consistently excellent results across a broad spectrum of patients. The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) was actively involved in the research and development of this stent through the Resolute U.S. trial. James Kong, M.D., cardiologist with the Ohio Heart and Vascular Center, treated the first patient in Greater Cincinnati.

Read the full story. (PDF)

Clinical Trial of Next Generation Heart Valve Device Expanded

2012-02-09T11:05:00.000-05:00

Physicians at The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital have enrolled and treated the first three patients in the U.S. in the randomized Cohort A of the PARTNER II Trial. This trial, sponsored by Edwards Lifesciences, is studying the company's next-generation Edwards SAPIEN XT transcatheter heart valve in the treatment of aortic stenosis.

Read the full story. (PDF)

The Christ Hospital First in U.S. to Implant New Bare Metal Stent

2011-12-07T11:35:00.001-05:00

Physicians at The Christ Hospital are first in the U.S. to implant the OMEGA bare metal stent as part of a clinical trial sponsored by Boston Scientific. This trial will test the OMEGA(tm) Platinum Chromium Bare-Metal Coronary Stent System for safety and efficacy in the treatment of coronary artery disease. Dean Kereiakes, MD, principal investigator for the study at The Christ Hospital, treated the first U.S. patient in the study. The patient, an 68-year-old man from Harrison, Ohio, is doing well and is available for interview.

Read the full story (PDF)

The Christ Hospital is First in U.S. to Implant and is the Highest Enrolling Site for Investigational Second Generation MR-Conditional Pacemaker through Clinical Trial at Lindner Research Center

2011-11-09T14:43:00.000-05:00

Edward J. Schloss, M.D., medical director of electrophysiology at The Christ Hospital, was the first in the U.S. to implant the Advisa MRI SureScan® Pacing System, Medtronic’s second-generation pacemaker system, as part of a clinical trial offered through The Carl and Edyth Lindner Center for Research and Education. The study is investigating whether this new system, designed to be compatible with magnetic resonance imaging (MRI) scanners, is safe and effective for use in the MRI environment on any body region.

Read the full story (PDF)

The Christ Hospital First in Ohio to Treat Patient with Drug-Coated Balloon

2011-11-09T11:31:00.001-05:00

Physicians at The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) have treated the first patient in the state of Ohio with the Moxy™ Drug Coated Balloon as part of LEVANT 2, a global, multi-center, randomized clinical trial evaluating the safety and efficacy of this device for the treatment of peripheral arterial disease (PAD). Monica Hunter, M.D., interventional cardiologist at The Christ Hospital and principal investigator at the Lindner Research Center, performed the case. The patient is doing well and has been discharged home.

Read the full story (PDF)

Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program

2011-11-08T16:31:00.000-05:00

Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION™ (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents. Results were presented today by PERSEUS clinical program Principal Investigators Louis Cannon, M.D., of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Michigan, and Dean Kereiakes, M.D., Medical Director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

Read the full story

The Christ Hospital First in Ohio to Treat Patient with Drug-Coated Balloon

2011-10-05T15:31:00.000-04:00

Physicians at The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) have treated the first patient in the state of Ohio with the Moxy™ Drug Coated Balloon as part of LEVANT 2, a global, multi-center, randomized clinical trial evaluating the safety and efficacy of this device for the treatment of peripheral arterial disease (PAD). Monica Hunter, MD, interventional cardiologist at The Christ Hospital and principal investigator at the Lindner Research Center, performed the case. The patient is doing well and has been discharged home.

Read the full story (PDF)

United Therapeutics faces bleak future for oral Remodulin approval with disappointing PAH results, lack of physician enthusiasm

2011-09-20T11:04:00.000-04:00

United Therapeutics' (NASDAQ:UTHR) oral Remodulin (treprostinil) faces a bleak future, experts said. The company still plans to file for FDA approval for the pulmonary arterial hypertension (PAH) treatment indication, despite its recent failure in the pivotal Phase III Freedom-C2 study. The failed combination therapy study (oral Remodulin combined with other first line PAH therapies) was described by physicians as the pivotal study which would likely mirror its realistic treatment setting.

Read the full story

The Christ Hospital First in Cincinnati to Use New Device Designed to Prevent Stroke in Patients with Common Heart Rhythm Disorder

2011-06-21T08:22:00.000-04:00

Physicians at The Christ Hospital are the first in Greater Cincinnati to implant the WATCHMAN Left Atrial Appendage Closure device as part of a clinical trial through the Carl and Edyth Lindner Center for Research and Education (Lindner Research Center). The trial is studying the capabilities of the WATCHMAN device to treat patients with atrial fibrillation (AF) who require blood-thinning medications to reduce their risk of stroke. This is a confirmatory study on a prior pivotal study that was completed in June 2008. This study will provide additional information on the safety and efficacy of the device for Food and Drug Administration (FDA) review. Madhukar Gupta, MD, an electrophysiologist with The Christ Hospital, performed the procedure on a 79-year-old woman from Milford, Ohio. The patient is doing well. Both Dr. Gupta and the patient are available for interviews.

Read the full story

Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System

2011-05-24T13:21:00.000-04:00

"The PROMUS Stent has demonstrated outstanding deliverability, low late loss and excellent safety in numerous clinical trials and extensive real-world practice," said Dean J. Kereiakes, MD, FACC, Medical Director, The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, and Professor of Clinical Medicine, Ohio State University. "These benefits make the PROMUS 2.25 mm Stent an attractive option for U.S. physicians treating patients with small vessels."

Read the full story

Cardiologists with The Christ Hospital are First in Greater Cincinnati Region to Perform Heart Valve Replacement without Open Heart Surgery

2011-05-10T08:35:00.000-04:00

Physicians at The Christ Hospital are first to bring pioneering technology to Greater Cincinnati that may provide a treatment option for patients with a common heart valve disorder who do not qualify for surgery. The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) is one of 20+ sites in the U.S. to participate in an investigational research trial using a novel therapy to treat severe aortic stenosis (AS), a condition that affects nearly 1.5 million Americans. The PARTNER (Placement of AoRTic traNscathetER valves) II Trial will evaluate transcatheter aortic valve replacement (TAVR), using the Edwards SAPIEN XT valve, in patients who are considered to be at high risk or inoperable for traditional valve replacement using open-heart surgery. The Christ Hospital is the only PARTNER II study site between Cleveland, Oh. and Atlanta, Ga.

Read the full story

Dean Kereiakes, MD, FACC, Receives Simon Dack Award for Outstanding Scholarship

2011-04-04T13:24:00.000-04:00

The editors of the Journal of the American College of Cardiology (JACC) honored Dean Kereiakes, MD, FACC, with the Simon Dack Award for Outstanding Scholarship on Sunday, April 3 at their editorial board meeting in New Orleans, La. The Simon Dack Award, named for the founding editor of JACC, recognizes peer reviewers who assist the journal in its mission of publishing important new clinical information. Since 2006, Dr. Kereiakes has submitted 78 editorial reviews to JACC and JACC Cardiovascular Interventions.

Read the full story (PDF)

The Christ Hospital First in Cincinnati to Study Novel Heart Failure Monitoring Device

2011-03-22T08:30:00.000-04:00

Physicians with The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (The Lindner Research Center) are the first in Cincinnati to implant an investigational left atrial pressure (LAP) monitoring device as part of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy (LAPTOP) investigational trial by St. Jude Medical. The device directly tracks pressure within the heart in real time. The pressure measurements are intended to help physicians determine how and when they should adjust a patient’s heart failure (HF) medications. Currently, there is no other means of obtaining LAP measurements outside the clinic or hospital setting. The goal of the trial is to prevent fluid retention in HF patients and also to prevent hospitalization, therefore improving quality of life. A 78-year-old man from Monroe, Ohio was the first patient to receive this device at The Christ Hospital in February, and is doing well. The device was implanted by Jay Schloss, MD, FACC, director of electrophysiology at The Christ Hospital Heart and Vascular Center. Both Dr. Schloss and the patient are available for interviews.

Read the full story